High-mobility group box-i isoforms as potential therapeutic targets in sepsis

Methods in Molecular Biology

Volumn 361, Issue , 2007, Pages 145-162

  Parrish, William ^a   Ulloa, Luis ^a  

^a NONE

Author keywords

HMGB1; Posttranslational modifications; Proinflammatory cytokines; Sepsis

Indexed keywords

CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; ISOPROTEIN;

ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; NECROSIS; PATHOLOGY; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS;

ANIMALS; ARTHRITIS, RHEUMATOID; CYTOKINES; HMGB1 PROTEIN; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; NECROSIS; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SEPSIS;

EID: 34547169543     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1385/1-59745-208-4:145     Document Type: Article

References (58)

1. Ulloa, L. and Tracey, K. J. (2005) The "cytokine profile": a code for sepsis. Trends Mol. Med. 11, 56-63.
2. Lotze, M. T. and Tracey, K. J. (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5, 331-342.
3. Ulloa, L. (2005) The vagus nerve and the nicotinic anti-inflammatory pathway. Nat. Rev. Drug Disc. 4, 673-684.
4. Ulloa, L., Ochani, M., Yang, H., et al. (2002) Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. PNAS 99, 12,351-12,356.
5. Messmer, D., Yang, H., Telusma, G., et al. (2004) High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J. Immunol. 173, 307-313.
6. Yang, H., Ochani, M., Li, J., et al. (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. PNAS 101, 296-301.
7. Scaffidi, P., Misteli, T., and Bianchi, M. E. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195.
8. Andersson, U., Wang, H., Palmblad, K., et al. (2000) High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 192, 565-570.
9. Park, J. S., Arcaroli, J., Yum, H.-K., et al. (2003) Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am. J. Physiol. Cell. Physiol. 284, C870-C879.
10. Li, J., Kokkola, R., Tabibzadeh, S., et al. (2003) Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mo1. Med. 9, 37-45.
11. Degryse, B., Bonaldi, T., Scaffidi, P., et al. (2001) The high mobility group (HMG) boxes of the nuclear protein HMG1 induce Chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J. Cell Biol. 152, 1197-1206.
12. Cossu, G. and Bianco, P. (2003) Mesoangioblasts-vascular progenitors for extravascular mesodermal tissues. Curr. Opin. Genet. Dev. 13, 537-542.
13. Palumbo, R., Sampaolesi, M., De Marchis, E., et al. (2004) Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J. Cell Biol. 164, 441-449.
14. Bonaldi, T., Talamo, F., Scaffidi, P., et al. (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO 22, 5551-5560.
15. Gardella, S., Andrei, C., Ferrera, D., et al. (2002) The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3, 995-1001.
16. Alexandrova, E. A. and Beltchev, B. G. (1988) Acetylated HMG1 protein interacts specifically with homologous DNA polymerase alpha in vitro. Biochem. Biophys. Res. Commun. 154, 91-927.
17. Dimov, S. I., Alexandrova, E. A., and Beltchev, B. G. (1990) Differences between some properties of acetylated and nonacetylated forms of HMG1 protein. Biochem. Biophys. Res. Commun. 166, 819-826.
18. Ugrinova, I., A, P. E., Armengaud, J., and Pashev, I. G. (2001) In vivo acetylation of HMG1 protein enhances its binding affinity to distorted DNA structures. Biochemistry 40, 14,655-14,660.
19. Li, J., Wang, H., Mason, J. M., et al. (2004) Recombinant HMGB1 with cytokinestimulating activity. J. Immunol. Methods. 289, 211-223.
20. Zimmermann, K., Volkel, D., Pable, S., et al. (2004) Native versus recombinant high-mobility group B1 proteins: functional activity in vitro. Inflammation 28, 221-229.
21. Park, J. S., Svetkauskaite, D., He, Q., et al. (2004) Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279, 7370-7377.
22. Akira, S. and Takeda, K. (2004) Toll-like receptor signalling. Nat. Rev. Immunol. 4,499-511.
23. Wang, H., Bloom, O., Zhang, M., et al. (1999) HMG-I as a late mediator of endotoxin lethality in mice. Science 285, 248-251.
24. Abraham, E., Arcaroli, J., Carmody, A., Wang, H., and Tracey, K. J. (2000) Cutting Edge: HMG-I as a Mediator of Acute Lung Inflammation. J. Immunol. 165, 2950-2954.
25. Pullerits, R., Jonsson, I. M., Verdrengh, M., et al. (2003) High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum. 48, 1693-1700.
26. Dumitriu, I. E., Baruah, P., Valentinis, B., et al. (2005) Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J. Immunol. 174, 7506-7515.
27. Dumitriu, I. E., Baruah, P., Bianchi, M. E., Manfredi, A. A., and Rovere-Querini, P. (2005) Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur. J. Immunol. 35, 2184-2190.
28. Fiuza, C., Bustin, M., Talwar, S., et al. (2003) Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101, 2652-2660.
29. Degryse, B. and Virgilio, M. (2003) The nuclear protein HMGB1, a new kind of chemokine? FEBS Lett. 553, 11-17.
30. Sappington, P. L., Yang, R., Yang, H., Tracey, K. J., Delude, R. L. and Fink, M. P. (2002). HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 123, 790-802.
31. Rauvala, H. and Pihlaskari, R. (1987) Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J. Biol. Chem. 262, 16,625-16,635.
32. Merenmies, J., Pihlaskari, R., Laitinen, J., Wartiovaara, J., and Rauvala, H. (1991) 30-kDa heparin-binding protein of brain (amphoterin) involved in neurite out-growth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J. Biol. Chem. 266, 16,722-16,729.
33. Parkkinen, J., Raulo, E., Merenmies, J., et al. (1993) Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J. Biol. Chem. 268, 19,726-19,738.
34. Kuniyasu, H., Oue, N., Wakikawa, A., et al. (2002) Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J. Pathol. 196, 163-170.
35. Yang, H., Wang, H., Czura, C. J., and Tracey, K. J. (2005) The cytokine activity of HMGB1. J. Leukoc. Biol. 78, 1-8.
36. Hori, O., Brett, J., Slattery, T., et al. (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. J. Biol. Chem. 270, 25,752-25,761.
37. Huttunen, H. J. and Rauvala, H. (2004) Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J. Intern. Med. 255, 351-366.
38. Schmidt, A. M., Yan, S. D., Yan, S. F., and Stern, D. M. (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 108, 949-955.
39. Kokkola, R., Andersson, A., Mullins, G., et al. (2005) RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand. J. Immunol. 61, 1-9.
40. Wang, H., Liao, H., Ochani, M., et al. (2004) Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med. 10, 1216-1221.
41. Huttunen, H. J., Fages, C., Kuja-Panula, J., Ridley, A. J., and Rauvala, H. (2002) Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res. 62, 4805-4811.
42. Hervio, L. S., Coombs, G. S., Bergstrom, R. C., Trivedi, K., Corey, D. R., and Madison, E. L. (2000) Negative selectivity and the evolution of protease cascades: the specificity of plasmin for peptide and protein substrates. Chem. Biol. 7, 443-453.
43. Li, M., Carpio, D. F., Zheng, Y., et al. (2001) An essential role of the NF-KB/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J. Immunol. 166, 7128-7135.
44. Dunne, A. and O'Neill, L. A. (2005) Adaptor usage and Toll-like receptor signaling specificity. FEBS Lett. 579, 3330-3335.
45. Rashid, A. J., O'Dowd, B. F., and George, S. R. (2004) Minireview: diversity and complexity of signaling through peptidergic G protein-coupled receptors. Endocrinology 145, 2645-2652.
46. Rios, C. D., Jordan, B. A., Gomes, I., and Devi, L. A. (2001) G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol Ther. 92, 71-87.
47. Mistry, A. R., Falciola, L., Monaco, L., et al. (1997) Recombinant HMG1 protein produced in Pichia pastoris: a nonviral gene delivery agent. Biotechniques 22, 718-729.
48. Bottger, M., Vogel, F., Platzer, M., Kiessling, U., Grade, K., and Strauss, M. (1988) Condensation of vector DNA by the chromosomal protein HMG1 results in efficient transfection. Biochim. Biophys. Acta. 950, 221-228.
49. Rubartelli, A. and Sitia, R. (1995) Entry of exogenous polypeptides into the nucleus of living cells: facts and speculations. Trends Cell Biol. 5, 409-412.
50. Dietz, G. P. and Bahr, M. (2004) Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol. Cell. Neurosci. 27, 85-131.
51. Krieg, A. M. (2002) CPG Motifs in bacterial DNA and their immune effects. Ann. Rev. Immunol. 20, 709-760.
52. Ulloa, L., Batliwalla, E M., Andersson, U., Gregersen, P. K., and Tracey, K. J. (2003) High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. Arthritis Rheum. 48, 876-881.
53. Parkkinen, J. and Rauvala, H. (1991) Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen activation by amphoterin. J. Biol. Chem. 266, 16,730-16,735.
54. Ramachandran, C., Yau, P., Bradbury, E., Shyamala, G., Yasuda, H., and Walsh, D. (1984) Phosphorylation of high-mobility-group proteins by the calcium-phospholipid-dependent protein kinase and the cyclic AMP-dependent protein kinase. J. Biol. Chem. 259, 13,495-13,503.
55. von Knethen, A., Tautenhahn, A., Link, H., Lindemann, D., and Brune, B. (2005) Activation-induced depletion of protein kinase Ca provokes desensitization of monocytes/macrophages in sepsis. J. Immunol. 174, 4960-4965.
56. Chen, L.-Y., Doerner, A., Lehmann, P. F., Huang, S., Zhong, G., and Pan, Z. K. (2005) A novel protein kinase C (PKCε) is required for fMet-Leu-Phe-induced activation of NF-κB in human peripheral blood monocytes. J. Biol. Chem. 280, 22,497-22,501.
57. Aksoy, E., Goldman, M., and Willems, F. (2004) Protein kinase C epsilon: a new target to control inflammation and immune-mediated disorders. Int. J. Biochem. Cell Biol. 36, 183-188.
58. Sterner, R., Vidali, G., and Allfrey, V. G. (1979) Studies of acetylation and deacetylation in high mobility group proteins. Identification of the sites of acetylation in HMG-1. J. Biol. Chem. 254, 11,577-11,583.